ERBP guideline on management of patients with diabetes and chronic kidney disease stage 3B or higher. Metformin for all?
Abstract
Alberto Martínez-Castelao, José Luis Górriz, Alberto Ortiz y Juan F. Navarro-González a Hospital Universitario Bellvitge, IDIBELL, Hospitalet, Barcelona, España b REDINREN, Instituto de Salud Carlos III, RD16/0009; GEENDIAB, España c Hospital Clínico Universitario, Valencia, España d IIS-Fundacion Jiménez Díaz, Universidad Autónoma de Madrid, Fundación Renal Iñigo Alvarez de Toledo-IRSIN, Madrid, España e Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, España
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.